Literature DB >> 2369751

DNA synthesis by L929 cells following doxorubicin exposure.

K W Lanks1, J M Lehman.   

Abstract

Doxorubicin does not kill L929 cells at concentrations that profoundly reduce clonogenic survival. Instead, the cell and nuclear volume progressively increase for at least 1 week following drug exposure leading to the production of characteristic giant cells. The increase in nuclear volume is due to continued DNA synthesis and increase in chromosome number without entry into mitosis. The implications of this finding for in vitro chemosensitivity assays and for the mechanism of doxorubicin cytotoxicity are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369751

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Lack of synchrony among multiple nuclei induces partial DNA fragmentation in V79 cells polyploidized by demecolcine.

Authors:  K Fujikawa-Yamamoto; C Ohdoi; H Yamagishi; Z P Zong; M Murakami; N Yamaguchi
Journal:  Cell Prolif       Date:  1999-12       Impact factor: 6.831

2.  Human diploid fibroblast cells in senescence; cycling through polyploidy to mitotic cells.

Authors:  Kirsten H Walen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

3.  Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation.

Authors:  J Lamb; D N Wheatley
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

4.  Spontaneous cell transformation: karyoplasts derived from multinucleated cells produce new cell growth in senescent human epithelial cell cultures.

Authors:  Kirsten H Walen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 May-Jun       Impact factor: 2.416

5.  The role of reduced nicotinamide adenine dinucleotide phosphate in glucose- and temperature-dependent doxorubicin cytotoxicity.

Authors:  J P Gao; S Friedman; K W Lanks
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.